AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03540537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block
Description: Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
Study NCT02080481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infiniti Plus needle guidance system
Description: The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
Study NCT01928459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
Study NCT01928459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 will be administered orally once daily on each day of the 28-day cycle.
Study NCT01835639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
Description: Supplements will be provided as oral capsules.
Study NCT01332175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provent®
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP
Study NCT01332175 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Provent®
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP
Study NCT01332175 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Provent®
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP
Study NCT01332175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP
Study NCT00797212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo Blood Glucose Monitoring System
Description: Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
Study NCT02080481 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional block needle
Description: conventional block needle used for insertion of femoral nerve catheters.
Study NCT02345772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant 500 mg
Description: Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
Study NCT04620200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg
Study NCT04620200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg
Study NCT03615612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: QuickSee refractive error assessment + glasses
Description: QuickSee refractive error assessment + glasses
Study NCT00640159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zelapar
Description: Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
Study NCT00463229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional Team Approach
Description: Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
Study NCT00982436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin
Description: Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
Study NCT00982436 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy in 35 fractions to gross tumor and lymph node metastases
Study NCT00982436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1.5 intravenous weekly during radiotherapy
Study NCT00210275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Educational Message
Description: Three forms of printed educational materials (short or long educational messages and patient reminder notes)
Study NCT04478487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medolac human milk based human milk fortifier (MHMHMF)
Description: MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
Study NCT01515241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CER-001
Description: Weekly injection
Study NCT02404441 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PDR001
Description: anti-PD1 antibody
Study NCT03387254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR + active brain stimulation
Description: Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
Study NCT03387254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR + sham brain stimulation
Description: Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
Study NCT02238041 — intervention group
Intervention type: DEVICE
Intervention: GlucoClear System
Study NCT03205566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400Mg Tab
Description: bd for 7 days
Study NCT03205566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine 150Mg Tablet
Description: + Raltegravir 400Mg tablet bd for 7 days
Study NCT02345772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
Study NCT02345772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab (H, 8mg/kg
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
Study NCT02345772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab (P, 840 mg
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
Study NCT02817113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
Study NCT02817113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
Study NCT02817113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
Study NCT02984241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Coping Skills Training
Description: Access to a specialized coping skills training website
Study NCT02984241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Usual Web Care
Description: Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
Study NCT02984241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coach Support
Description: Access to a professional coach by phone
Study NCT02306863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibrating chair
Description: vibration provided via physioacoustic method
Study NCT02306863 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Description: simulated whole-body vibration
Study NCT00898300 — intervention group
Intervention type: OTHER
Intervention: biologic sample preservation procedure
Study NCT00898300 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Study NCT04373408 — intervention group
Intervention type: PROCEDURE
Intervention: ACL repair without anterolateral repair
Description: Surgical repair of the ACL using semitendinous autograft
Study NCT04373408 — intervention group
Intervention type: PROCEDURE
Intervention: ACL repair with anterolateral repair
Description: Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
Study NCT02214225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: One 0.5 mL intramuscular dose into the deltoid muscle
Study NCT02214225 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine (TIV-1)
Description: One 0.5 mL intramuscular dose into the deltoid muscle.
Study NCT02214225 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine (TIV-2)
Description: One 0.5 mL intramuscular dose into the deltoid muscle.
Study NCT01673815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video (played on a computer monitor)
Description: The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
Study NCT03029078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplant
Description: We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
Study NCT03040011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Study NCT03040011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Study NCT03040011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Study NCT03040011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Pudendal Nerve Block
Description: Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
Study NCT03040011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Pudendal Nerve Block
Description: Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
Study NCT03040011 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral Pudendal Nerve Block
Description: Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
Study NCT03040011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Levator Ani Muscle Injection
Description: Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
Study NCT03040011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Levator Ani Muscle Injection
Description: Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
Study NCT03040011 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral Levator Ani Muscle Injection
Description: Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
Study NCT03040011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
Study NCT02938078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avenova Lid Cleanser
Description: Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
Study NCT01792375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent membrane sweeping with Dinoprostone
Description: Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix.
Study NCT01792375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Dinoprostone vaginal insert
Description: For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening
Study NCT02520258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Description: OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
Study NCT02520258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Description: OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
Study NCT02520258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet soda containing aspartame only
Description: 7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
Study NCT00621556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (Synthetic Human Secretin)
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study NCT01375803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel dietary fiber
Description: oral consumption in beverage
Study NCT01375803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel dietary fiber
Description: Oral consumption in beverage
Study NCT01375803 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral consumption in beverage
Study NCT03840772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Treatment with eribulin
Study NCT02891148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Study NCT00686985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, docetaxel
Description: Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
Study NCT02805751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early loading on a training pedal
Description: The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
Study NCT02805751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tendon strain exercises
Description: The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
Study NCT02805751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tendon strain exercises
Description: The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
Study NCT02805751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early weight bearing
Description: The patients are allowed to bear weight as much as tolerated in the walker from day 1.
Study NCT02805751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early weight bearing
Description: The patients are allowed to bear weight as much as tolerated in the walker from day 1.
Study NCT02645877 — intervention group
Intervention type: PROCEDURE
Intervention: Prehospital care
Description: The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
Study NCT00882583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
Study NCT00882583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral Dasatinib Days 8 through 64.
Study NCT03712618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion - LONG Platelet Transfusion
Description: Platelets Transfused over 4-HOURS